Clinical trial
Combination Bortezomib and Rituximab in Patients With Waldenstrom's…
NCT00422799 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00422799 |
|---|---|
| Title | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) |
| Official title | Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Bortezomib, Rituximab |
| Enrollment | 63 |
| Start date | Aug 30, 2006 |
| Primary completion | Oct 9, 2015 |
| Completion | Oct 9, 2015 |
| First posted | Jan 17, 2007 |
| Last update posted | Oct 27, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: